Aarhus University Seal / Aarhus Universitets segl

Finn Skou Pedersen

Professor

Profile photo

Finn Skou Pedersen

Professor

  • Institut for Molekylærbiologi og Genetik - Genekspression og Genmedicin
  • Interdisciplinary Nanoscience Center - INANO-MBG, Gustav Wied 10
Postaddresse:
C.F. Møllers Allé 3
1131, 530
8000
Aarhus C
Danmark
Postaddresse:
Gustav Wieds Vej 10
8000
Aarhus C
Danmark

E-mail: fsp@mbg.au.dk

Telefon: +4587155475

CURRICULUM VITAE

FINN SKOU PEDERSEN, November 24, 1948, Danish citizen
Home Address: Præstehaven 47, DK-8210 Aarhus, Tel.: ++4586155654
Office: +45 87150000; direct, +45 87155475, e-mail: fsp@mb.au.dk; fax.: +45 8619 6500 and/or +45 8612 3178

Education:
1973 M.Sc. (Cand. scient.), biology and biochemistry, Univ. of Copenhagen/Univ. of Aarhus.
1976 Ph.D. in molecular biology, The Faculty of Natural Sciences, University of Aarhus.

Appointments:
1973 1976: Research fellow at Department of Molecular Biology, Aarhus University;
1976 1979/80: Post doctoral research associate at Sidney Farber Cancer Institute, Harvard Medical School, Boston, Mass., USA (Laboratory of W.A. Haseltine).
1980 1995: Associate professor at Department of Molecular Biology, University of Aarhus.
1995 2005: Professor in oncological molecular biology, Department of Molecular and Structural Biology, Department of Medical Microbiology and Immunology, University of Aarhus.
2005- :Professor in Retroviral Molecular Biology, Dept. of Molecular Biology, Univ. of Aarhus



Academic work:
- more than 200 international publications (excluding abstracts), including 191 original scientific papers in peer reviewed journals, 10 peer-reviewed survey-papers and more than 30 published, independent patents.
- Principal supervisor for 111 M.Sc. projects and 51 Ph.D. projects (49 completed and 2 ongoing).
- Grant application reviewer for many national and international foundations; member of the Medical and Scientific Board of the Danish Cancer Society, 2000-2005; Panel evaluator for The Norwegian Cancer Society 2007-11 & 2011-14; member of more than 10 review panels of the European Commission.
- Member of the editorial boards of Retrovrology (2004-10) and Advances in Virology (2008-). Reviewer of on the average two manuscripts per month for journals in molecular biology, genetics, virology, cancer research, and biotechnology (e.g. Nucl. Acids Res.. Nature Methods, Nature Struc. Biol., J. Mol. Biol., PNAS, Oncogene, Human Molecular Genetics, RNA, J. Virol., Mol. Cell. Biol.).
- Member of numerous thesis committees and committees for academic appointments, including ten professor appointments.

Memberships, chairmanships:
Contract partner in 4 successive EURATOM shared cost research contracts (1983–1999); Corresponding member, European Late Effects Project Group (1984-); Chairman, Biological Society of Jutland (1985-93); Danish representative, Planning group for gene technology, Nordic Council of Ministers (1988 92);
Representative, The National Committee for Biochemistry (1988 94); Board member, The Danish Centre for Human Genome Research (1991 98); Coordinator, international EC BRIDGE shared cost research contract (retroviral vectors) (1991 93 ); Member of Danish Natural Science Academy (1992 ); Administrative head (chairman) of the Dept. of Molecular Biology, Aarhus University (1994 95); Member of the executive board, Faculty of Natural Science (1994 95); Coordinator, EC Biotechnology 2 shared cost research contract (Retroviral vectors) (1995 98); Sector coordinator, EC Biotechnology Programme (Gene Therapy contracts, 1995 98); Member, ACTIP (Animal Cell Technology Industrial Platform (1995 99); Contract partner, EC BioMed concerted action (Gene therapy for AIDS, 1996 99); Member, Scientific Advisory Board, Bavarian Nordic Research Institute A/S (1997–2000) ; Member, Scientific Advisory Board, M & E Biotech A/S (now Pharmexa) (1997–2000); Member of the Royal Danish Academy of Sciences and Letters (1998 ); Member the Intellectual property board, Aarhus University (1999 2004); Member of the Medical and Scientific Board of The Danish Cancer Society (2000-2005); Member of the patent board, Aarhus University (2000-); Consultant to Sagres Discovery, Davis, CA, USA (2000-2003): Advisor to Picobella LP, Burlingame, CA, USA (2003- ); Programme director of the Danish siRNA Delivery Centre (2003- ); Co-founder of Retrovec ApS (2004- ); Member of the Advisory Board of the Center for Molecular Clinical Cancer Research (2005-); Co-founder of InVitroQ ApS (2005); Member of the Evaluation committee for Carlsbergs Mindelegat for Brygger J. C. Jacobsen (2005-08), Co-founder of EnFutech ApS (2007), Co-founder of SKAU Vaccines (2007), Panel evaluator for The Norwegian Cancer Society (2007-11 & 2011-14). Co-founder of Zymonositics (2013).

Research interests:
University of Aarhus, 1972-76: Regulation of the synthesis of guanosinetetra- and –pentaphosphates in Escherichia coli. Key publication: Pedersen, F.S., Lund, E. & Kjeldgaard N.O.: Codon specific tRNA dependent in vitro synthesis of ppGpp and pppGpp. Nature (London) New Biol. 243, 13-15 (1973).
Harvard Medical School, 1976–79/80: Genome variation and biology of murine leukemia viruses and other retroviruses. Key publication: Pedersen, F.S., Crowther, R.L., Tenney, D.Y., Reimold, A. & Haseltine, W.A.: Novel leukaemogenic retroviruses isolated from a tumour cell line derived from a spontaneous AKR tumour. Nature (London) 292, 167-170 (1981)
Aarhus University, 1980–present: Molecular retrovirology, including retroviral replication, virus-host interactions, retroviral gene transfer and retroviral pathogenicity. In the later years, the research also includes other aspects of gene and cell technology. Has since 1980 authored 47 original papers in J. Virol., the leading journal of experimental virology.


Original peer-reviewedpublications:

1.Pedersen, F.S., Lund, E. & Kjeldgaard N.O.: Codon specific tRNA dependentin vitro synthesis of ppGpp and pppGpp. Nature (London) New Biol. 243, 13-15(1973).

2.Friesen, J.D., Parker, J., Watson, R.J., Fiil, N.P., Pedersen, S. & Pedersen,F.S.: Isolation of a lambda transducing bacteriophage carrying the relA geneproduct of Escherichia coli. J. Bacteriol. 127, 917-924 (1976).

3.Pedersen, F.S. & Kjeldgaard, N.O. Analysis of the relA gene product ofEscherichia coli. Eur. J. Biochem. 76, 91-97 (1977)

4.Desselberger, U., Nakajima, K., Alfino, P., Pedersen, F.S., Haseltine, W.A.,Hannoun, C. & Palese, P.: Biochemical evidence that new influenza virusstrains in nature may arise by recombination (reassortment). Proc. Natl. Acad.Sci. USA 75, 3341-3345 (1978)

5.Pedersen, F.S. & Haseltine, W.A.: Characterization of the genome of anendogenous, ecotropic retrovirus of the AKR strain of mice. A micromethod fordetailed characterization of high-molecular weight RNA. J. Virol. 33, 349-365(1980).

6.Pedersen, F.S., Buchhagen, D.L., Chen, C.Y., Hays, E.F. & Haseltine, W.A.:Characterization of virus produced by a lymphoma induced by inoculation of MCF247 virus. J. Virol. 35, 211-218 (1980).

7.Rosenberg, Z.F., Pedersen, F.S. & Haseltine, W.A.: Comparative analysis ofthe genomes of Feline leukemia viruses. J. Virol. 35, 542-546 (1980).

8.Buchhagen, D.L., Pedersen, F.S., Crowther, R.L. & Haseltine, W.A.: Mostsequence differences between the genomes of the AKR virus and an in vitro passaged,leukemogenic Gross A virus are located near the 3' terminus. Proc. Natl. Acad.Sci. USA 77, 4359-4364 (1980)

9.Clements, J.E., Pedersen, F.S., Narayan, O. & Haseltine, W.A: Genomicchanges associated with antigenic variation of Visna virus during persistentinfection. Proc. Natl. Acad. Sci. USA 77, 4454-4458 (1980)

10.Pedersen, F.S., Crowther, R.L., Tenney, D.Y., Reimold, A. & Haseltine,W.A.: Novel leukaemogenic retroviruses isolated from a tumour cell line derivedfrom a spontaneous AKR tumour. Nature 292, 167-170 (1981)

11.Pedersen, F.S., Crowther, R.L., Hays, E.F., Nowinski, R.C. & Haseltine,W.A.: Structure of retroviral RNAs produced by cell lines derived fromspontaneous lymphomas of AKR mice. J. Virol. 41, 18-29 (1982)

12.Schmidt, J., Erfle, V., Pedersen, F.S., Rohmer, H., Schetters, H., Marquardt,K.-H. & Luz, A.: Oncogenic retrovirus from spontaneous murine osteomas. I.Isolation and biological characterization. J. Gen. Virol. 65, 2237 (1984).

13.Michiels, L., Maisin, J.R., Pedersen, F.S. & Merregaert, J.:Characterization of the FBR-Murine osteosarcoma virus complex: FBR-MuSV encodesa fos derived oncogene. Int. J. Cancer 33, 511-517 (1984).

14.Etzerodt, M., Mikkelsen, T., Pedersen, F.S., Kjeldgaard, N.O. & Jørgensen,P.: The nucleotide sequence of the Akv murine leukemia virus genome. Virology134, 196-207 (1984).

15.Leib-Mösch, C., Schmidt, J., Etzerodt, M., Pedersen, F.S. Hehlmann, R., &Erfle, V.: Oncogenic retrovirus from spontaneous murine osteomas. II. Molecularcloning and genomic characterization. Virology 150, 96-105 (1986).

16.Jensen, N.A., Jørgensen, P., Kjeldgaard, N.O. & Pedersen, F.S.: Mammalianexpression-and -transmission vector derived from Akv murine leukemia virus.Gene 41, 59-65 (1986)

17.Pedersen, F.S. & Etzerodt, M.: Structure of endogenous retrovirusesexpressed in radiation-induced and spontaneous murine bone tumours. LeukemiaRes., 10, 923-930. (1986).

18.Justesen, J., Lund, T., Pedersen, F.S. & Kjeldgaard, N.O.: The physiologyof stringent factor (ATP:GTP 3' diphospho-transferase) in E.coli. Biochimie 68,715-722 (1986)

19.Jørgensen, P., Mikkelsen, T., Pedersen, F.S. & Kjeldgaard, N.O.: A MuLVtransmission vector system designed to permit recovery in E.coli of proviraland cellular flanking sequences. Virus Genes 1, 221-233, (1988).

20.Jørgensen, E.C., Kjeldgaard, N.O., Pedersen, F.S., & Jørgensen, P.: Anucleotide substitution in the gag N terminus of the endogenous DBA/2 virusprevents Pr65-gag myristylation and virus replication. J. Virol. 62, 3217-3223(1988).

21.Høllsberg, P., Møller-Larsen, A., Pedersen, F.S., Justesen, J., Hansen, H.J.,& Haahr, S.: Search for a retrovirus in long-term cultured cerebrospinalfluid cells and peripheral blood mononuclear cells from patients with multiple sclerosis.Acta Neurol. Scand., 80, 603-609 (1989).

22.Paludan,K., Dai,H.Y., Duch,M., Jørgensen,P., Kjeldgaard,N.O., andPedersen,F.S.: Different relative expression from two murine leukemia viruslong terminal repeats in unintegrated transfected DNA and in integratedretroviral vector proviruses. J. Virol. 63, 5201 - 5207 (1989).

23.Paludan,K., Duch,M., Jørgensen,P., Kjeldgaard,N.O., and Pedersen, F.S.:Graduated resistance to G418 leads to differential selection of culturedmammalian cells expressing the neo gene. Gene 85, 421-426 (1989).

24.Pallisgaard,N., Mikkelsen,T., Pedersen,F.S., Kjeldgaard,N.O., and Jørgensen,P.The nucleotide sequence of the 3' region of the murine leukemia virus SL16c4.Nucl. Acids Res. 17, 6413 (1989).

25.Dai.H.Y., Etzerodt,M., Bækgaard,A.J., Lovmand,S., Jørgensen,P.,Kjeldgaard,N.O., and Pedersen,F.S.: Multiple sequence elements in the U3 regionof the leukemogenic murine retrovirus SL3-2 contribute to cell-dependent geneexpression. Virology 175, 581-585 (1990).

26. Lovmand,S., Kjeldgaard, N.O., Jørgensen, P., and Pedersen, F.S.: Enhancer functions inU3 of Akv virus: A role for cooperativity of a tandem repeat unit and itsflanking DNA sequences. J. Virol. 64, 3185-3191 (1990).

27.Olsen, H.S., Lovmand, S., Lovmand, J., Jørgensen, P., Kjeldgaard, N.O., andPedersen, F.S.: Involvement of Nuclear Factor I binding sites in control of Akvvirus gene expression. J. Virol. 64, 4152-4161 (1990).

28.Duch, M., Paludan, K., Pedersen, L., Jørgensen, P., Kjeldgaard, N.O., and Pedersen,F.S.: Determination of transient or stable neo-expression levels in mammaliancells. Gene 95, 285-288 (1990).

29. Pedersen, L., Strauss, P.G., Schmidt, J., Luz, A.,Erfle. V., Jørgensen, P.,Kjeldgaard, N.O., and Pedersen F. S.: Pathogenicity of endogenous N-tropicBALB/c viruses. Virology 179, 931-935 (1990).

30.Morrison, H.L., Dai, H.Y., Pedersen, F.S., and Lenz, J.: Analysis of thesignificance of two single base-pair differences in the SL3-3 and Akv viruslong terminal repeats. J. Virol. 65, 1019-1022 (1991).

31.Hallberg, B., Schmidt, J., Luz, A., Pedersen, F.S., and Grundström, T.: SL3-3Enhancer Factor 1 transcriptional activators are required for tumor formationby SL3-3 murine leukemia virus. J. Virol. 65, 4177-4181 (1991).

32.Jørgensen, P., Mikkelsen, T., Pedersen, K., Pedersen, F.S., and Kjeldgaard,N.O.: Tagging the genome of the murine leukemia retrovirus SL3-3 by a bacteriallac operator sequence. Gene 109, 243-248 (1991).

33.Sørensen, M.S., Duch, M., Paludan, K., Jørgensen, P., and Pedersen, F.S.:Measurement of hygromycin B phosphotransferase activity in mammalian cellextracts by a simple dot-assay. Gene 112, 257-260 (1992).

34.Pedersen, K., Lovmand, S., Jørgensen, E.C.B., Pedersen, F.S., and Jørgensen,P.: Efficient expression and replication of murine leukemia virus with majordeletions in the enhancer region of U3. Virology 187, 821-824 (1992).

35.Jørgensen, E.C.B., Pedersen, F.S., and Jørgensen, P.: Matrix protein of Akvmurine leukemia virus: Genetic mapping of regions essential for particleformation. J. Virol. 66, 4479-4487 (1992).

36.Nielsen, A.L., Pallisgaard, N., Pedersen, F.S., and Jørgensen, P.: Murinehelix-loop-helix transcriptional activator proteins binding to the E-box motifof the Akv murine leukemia virus enhancer identified by cDNA cloning. Mol.Cell. Biol. 12, 3449-3459 (1992)

37.Pedersen, L., Behnisch, W., Schmidt, J., Luz, A., Pedersen, F.S., Erfle, V. andStrauss, P.G.: Molecular cloning of osteoma-inducing replication-competentmurine leukemia viruses from the RFB osteoma virus stock. J. Virol. 66,6186-6193 (1992).

38.Nørby, P.L., Pallisgaard, N., Pedersen, F.S., and Jørgensen, P.: Determinationof recognition sequences for DNA-binding proteins by a polymerase chainreaction assisted binding site selection method (BSS) using nitrocelluloseimmobilized DNA binding protein. Nucl. Acids Res. 20, 6317-6321 (1992).

39.Lund, A.H., Duch, M., Lovmand, J., Jørgensen, P. and Pedersen, F.S.: Mutatedprimer binding sites interacting with different tRNAs allow efficient murineleukemia virus replication. J. Virol. 67, 7125-7130 (1993).

40.Sørensen, A.B., Duch, M., Jørgensen, P. and Pedersen, F.S.: Amplification andsequence analysis of DNA flanking integrated proviruses by a simple two-steppolymerase chain reaction method. J. Virol. 67, 7118-7124 (1993).

41.Duch, M., Paludan, K., Lovmand, J., Pedersen, L., Jørgensen, P. and Pedersen,F.S.: A correlation between dexamethasone inducibility and basal expressionlevels of retroviral vector proviruses. Nucl. Acids Res. 21, 4777-4782 (1993).

42.Pallisgaard, N., Nielsen, A.L., Pedersen, F.S., Birkelund. S. and Jørgensen,P.: A common poly-linker in a set of vectors for expression of eukaryotic genesin mammalian and insect cells and bacterial cells. Gene 138, 115-118 (1994).

43.Nørby, P.L., Pallisgaard, N., Pedersen, F.S. and Jørgensen, P.: DNA recognitionsequence determination directly on plaques of a λ expressed recombinant DNAbinding protein. Anal. Biochem. 218, 476-478 (1994).

44.Duch, M., Paludan, K., Jørgensen, P. and Pedersen, F.S.: Lack of correlationbetween basal expression levels and susceptibility to transcriptional shut-downamong single-gene murine leukemia virus vector proviruses. J. Virol. 68,5596-5601 (1994).

45.Nielsen, A.L., Pallisgaard N., Pedersen, F.S. and Jørgensen, P.:Basic-helix-loop-helix proteins in murine C-type retrovirus transcriptionalregulation. J. Virol. 68, 5638-5647 (1994).

46.Duch, M., Paludan, K., Lovmand, J., Jørgensen, P. and Pedersen, F.S.: Theeffect of selection for high-level vector expression on the genetic andfunctional stability of a single transcript vector derived from alow-leukemogenic murine retrovirus. Hum. Gene Ther. 6, 289-296 (1995).

47.Pedersen, L., Johann, S.V., van Zeijl, M., Pedersen, F.S. and O'Hara, B.:Chimeras of receptors for gibbon ape leukemia virus/feline leukemia virus B andamphotropic murine leukemia virus reveal different modes of receptorrecognition by retrovirus. J. Virol. 69, 2401-2405 (1995).

48.Bonven, B.J., Nielsen, A.L., Nørby, P.L., Pedersen, F.S. and Jørgensen, P.:E-box variants direct formation of distinct complexes with the basichelix-loop-helix protein ALF1.J. Mol. Biol. 249, 564-575 (1995).

49.Lund, A.H., Duch, M. and Pedersen, F.S.: Increased cloning efficiency bytemperature cycle ligation. Nucl. Acids. Res. 24, 800-801 (1996).

50.Mikkelsen, J.G., Lund, A.H., Kristensen, K.D., Duch, M., Sørensen, M.S.,Jørgensen, P., and Pedersen, F.S.: A preferred region for recombinational patchrepair in the 5'untranslated region of primer binding site-impaired murineleukemia virus vectors. J. Virol. 70, 1439-1447 (1996).

51.Nielsen, A.L., Nørby, P.L., Pedersen, F.S., and Jørgensen, P.: Various modes ofBasic helix-loop-helix mediated regulation of murine leukemia virustranscription in lymphoid cell lines. J. Virol. 70, 5893-5901 (1996).

52.Nielsen, A.L.,Nørby, P.L., Pedersen, F.S., and Jørgensen, P.: E-box sequenceand context dependent TAL1 modulation of basic helix-loop-helix proteinmediated transcriptional activation. J. Biol. Chem. 271, 31463-31469 (1996)

53.Sørensen, A.B., Duch, M. Amtoft, H.W., Jørgensen, P., and Pedersen, F.S.:Sequence tags of provirus integration sites in DNAs of tumors induced by themurine retrovirus SL3-3. J. Virol 70, 4063-4070 (1996).

54.Østergaard, M., Pedersen, L., Schmidt, J., Luz, A., Lovmand, J., Erfle, V.,Pedersen, F.S., and Strauss, P.G.: Mapping of a major osteomagenic determinantof murine leukemia virus RFB-14 to non-LTR sequences. J. Virol. 71, 645-649(1997).

55.Ethelberg, S., Hallberg, B., Lovmand, J., Schmidt, J., Luz, A., Grundström, T.,and Pedersen, F.S.: Second site proviral enhancer alterations induced byenhancer mutants of SL3-3 murine leukemia virus: Negative effect of nuclearfactor 1 binding site. J. Virol. 71, 1196-1206 (1997).

56.Lund, A.H., Duch, M., Lovmand, J., Jørgensen, P., and Pedersen, F.S.:Complementation of a primer binding site-impaired murine leukemia virus-derivedretroviral vector by a genetically engineered tRNA-like primer. J. Virol. 71,1191-1195 (1997).

57.Jespersen, T., Duch, M., and Pedersen, F.S.: Efficient non-PCR overlapextension of PCR fragments by exonuclease end-polishing. BioTechniques. 23,48-52 (1997).

58.Amtoft, H.W., Sørensen, A.B., Bareil, C., Schmidt, J., Luz, A., and Pedersen,F.S.: Stability of AML1 (core) site enhancer mutations in T-lymphomas inducedby attenuated SL3-3 murine leukemia virus mutants. J. Virol. 71, 5080-5087(1997).

59.Ethelberg, S, Lovmand, J., Schmidt, J., Luz, A. and Pedersen, F.S.: Increasedlymphomagenicity and restored disease specificity of AML1 site (core) mutantSL3-3 murine leukemia virus by a second site enhancer variant evolved in vivo.J. Virol. 71, 7273-7280 (1997).

60.Ethelberg, S., Sørensen, A.B., Schmidt, J., Luz, A. and Pedersen, F.S.: AnSL3-3 murine leukemia virus enhancer variant more pathogenic than the wild typeobtained by assisted molecular evolution in vivo. J. Virol. 71, 9796-9799(1997).

61.Mikkelsen, J.G., Lund, A.H., Dybkær, K., Duch, M. and Pedersen, F.S.: Extendedminus-strand DNA as template for R-U5-mediated second-strand transfer inrecombinational rescue of primer binding site-modified retroviral vectors. J.Virol. 72, 2519-2525 (1998).

62.Lundorf, M..D, Pedersen, F.S., O’Hara, B., and Pedersen, L.: Single amino acidinsertion in loop 4 confers amphotropic murine leukemia virus receptor functionupon murine Pit1. J. Virol. 72, 4524-4527 (1998).

63.Lovmand, J., Sørensen, A.B., Schmidt, J., Østergaard, M., Luz, A., andPedersen, F.S.: B-cell lymphoma induction by Akv murine leukemia virusesharboring one or both copies of the tandem repeat in the U3 enhancer. J. Virol.72, 5745-5756 (1998).

64.Mikkelsen, J. G., Lund, A.H., Duch, M., and Pedersen, F.S.: Recombination inthe 5' leader of murine leukemia virus is accurate and influenced by sequenceidentity with a strong bias toward the kissing-loop dimerization domain. J.Virol. 72, 6967-6978 (1998).

65.Uckert, W., Willimsky, G., Pedersen, F.S., Blankenstein, T., and Pedersen, L.:Expression of human retrovirus receptors Pit1 and Pit2 does not correlate withinfectibility by three retroviral vector pseudotypes. Human Gene Ther. 9, 2619- 1627 (1998).

66.Lundorf, M.D., Pedersen, F.S., O’Hara, B. and Pedersen, L.: Amphotropic murineleukemia virus entry is determined by a combination of residues in Pit2 loops 2and 4. J. Virol. 73, 3169-3175 (1999).

67.Lund, A.H., Schmidt, J., Luz, A., Sørensen, A.B., Duch, M., and Pedersen, F.S.:Replication and pathogenicity of primer binding site mutants of SL3-3 murineleukemia viruses. J. Virol. 73, 6117-6122 (1999).

68.Duch , M., Tolstrup, A., Dalum, I., Jespersen, T., Mouritsen, S., and Pedersen,F.S.: Functional testing of a bicistronic retroviral vector for intracellularpeptide production. BioTechniques 26, 1032-1036 (1999).

69.Lund, A.H. and Pedersen, F.S.: The nucleotide sequence of the high-leukemogenicmurine retrovirus SL3-3 reveals a patch of mink cell focus forming-likesequences upstream of the ecotropic envelope gene. Arch. Virol. 144, 2207-2212(1999).

70.Mikkelsen, J.G., Lund, A.H., Duch, M., and Pedersen, F.S.: Forced recombinationof -modified murine leukemia virus-based vectors with MLEV and VL30 murineendogenous retroviruses. J. Gen. Virol. 80, 2957-2968 (1999).

71.Lund, A.H., Mikkelsen, J.G., Schmidt, J., Duch, M., and Pedersen, F.S.: Thekissing-loop motif is a preferred site of 5'leader recombination duringreplication of SL3-3 murine leukemia viruses in mice. J. Virol. 73, 9614-9618(1999).

72.Jespersen, T., Duch, M., Carrasco, M. L., Warming, S., and Pedersen, F.S.:Expression of heterologous genes from an IRES translational cassette inreplication-competent murine leukemia virus vectors. Gene, 239, 227-235 (1999).

73.Ethelberg, S., Tzschaschel, B. D., Luz, A., Diaz-Cano, S.J., Pedersen, F.S.,and Schmidt, J.: Increased induction of osteopetrosis, but unalteredlymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclearfactor 1 site in the enhancer. J. Virol. 73, 10406-10415 (1999).

74.Fang J, Zhu B, Wang DB, Chen CQ, Duch MR, Pedersen FS. Overexpressed Human TNFReceptor-75 Can Independently Mediate hTNFalpha-induced Cytotoxicity in BHK-21Cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai).1999;31(6):637-642. PubMed PMID: 12110927.

75.Mikkelsen, J.G., Lund, A.H., Duch, M., and Pedersen, F.S.: Mutations of thekissing loop dimerization sequence influence site specificty of murine leukemiavirus recombination in vivo. J. Virol. 74, 600-610 (2000).

76.Dreyer, K., Pedersen, F. S. and Pedersen, L.: A 13 amino acid Pit-1 specificloop 4 sequence confers feline leukemia virus subgroup B receptor function uponPit2. J. Virol. 74, 2926-2929 (2000).

77.Sørensen, A. B., Lund, A. H., Ethelberg, S., Copeland, N. G., Jenkins, N. A.and Pedersen, F. S.: Sint1, a common integration site in SL3-3 induced T-celllymphomas, harbors a putative oncogene with homology to the septin gene family.J. Virol. 74, 2161-2168 (2000).

78.Modin, C., Pedersen, F. S. and Duch, M.: Comparison of DNA polymerases forquantification of single nucleotide differences by primer extension assays.BioTechniques. 28, 48-50 (2000).

79.Lund, A.H., Duch, M., and Pedersen, F.S.: Selection of functional tRNA primersand primer binding site sequences from a retroviral combinatorial library.Nucl. Acids Res. 28, 791-799 (2000).

80.Dybkær, K., Pedersen, B., Pedersen, F.S., and Kristensen, J.S.: Identificationof acute myeloid leukemia patients with diminished expression of CD13 myeloidtranscripts identified by competitive reverse transcription polymerase chainreaction (RT-PCR). Leukemia Res. 24, 497-506 (2000).

81.Lund, A.H., Schmitz, A., Pedersen, F.S, and Duch, M.: Identification of a novelhuman tRNASer (GCA) functional in MLV replication. Biochim. Biophys. Acta 1492,264-268 (2000).

82.Modin, C., Pedersen, F.S. and Duch, M.: Lack of shielding of PBS-silencermediated repression of an internal promoter in a retroviral vector by theputative insulators scs, BEAD-1 and HS4. J. Virol.,74, 11697-11707 (2000).

83.Modin, C., Lund, A.H., Schmitz, A., Duch, M. and Pedersen, F.S.: Alleviation ofmurine leukemia virus repression in embryoninc carcinoma cells by geneticallyengineered primer binding sites and artificial tRNA primers. Virology 278,368-379 (2000).

84.Dybkær, K., Olesen, G., Pedersen, F.S., and Kristensen, J. S.: Stroma mediateddown-regulation of CD13 in patients with acute myeloid leukemia. Eur. J.Haematol., 66, 168-177 (2001).

85.Nielsen, L. B., Pedersen, F.S., and Pedersen, L.: Expression of type IIIsodium-dependent transporters/retroviral receptors mRNAs during osteoblastdifferentiation. Bone, 28, 160-166 (2001).

86.Dybkær, K., Kristensen, J.,S. and Pedersen, F.S.: Single site polymorphism andalternative splicing of the human CD13 gene - different splicing frequenciesamong patients with acute myeloid leukemia and healthy persons. Brit. J.Haematol.112, 691-696 (2001).

87.Tolstrup, A.B., Duch, M., Dalum, I., Pedersen, F.S. and Mouritsen, S.:Functional screening of retroviral peptide library for MHC class Ipresentation. Gene 263, 77-84 (2001).

88.Hansen, A.C., Grunwald, T., Lund, A. H., Schmitz, A., Duch, M., Überla, K, andPedersen, F.S.: Transfer of primer binding site mutated simian immunodeficiencyvirus vectors by genetically engineered artificial and hybrid tRNA-likeprimers. J. Virol. 75, 4922-4928 (2001).

89.Martin-Hernandez, J., Sørensen, A.B. and Pedersen, F.S.: Murine Leukemia Virusproviral insertions between the N-ras and unr genes in B-cell lymphoma DNAaffect the expression of N-ras only. J.Virol 75, 11907-12 (2001).

90.Sørensen, A. B., Warming, S., Füchtbauer, E.-M. and Pedersen, F.S.: Alternativesplicing, expression and gene structure of the septin-like putativeproto-oncogene Sint1. Gene 285 79-89 (2002).

91.Bachrach, E., Pelegrin, M., Piechaczyk, M., Pedersen, F.S., and Duch, M.:Efficient gene transfer into spleen cells of newborn mice by areplication-competent retroviral vector. Virology, 293, 328-334 (2002).

92.Schmitz, A., Lund, A.H., Hansen, A.C., Duch, M. and Pedersen, F.S.: Target-cellderived tRNA-like primers for reverse transcription support retroviralinfection at low efficiency. Virology 297, 68-77 (2002).

93.Rasmussen, S.V., J.G. Mikkelsen and F.S. Pedersen: Modulation of homo- andheterodimerization of Harvey sarcoma virus RNA by GACG tetraloops and pointmutations in palindromic sequences. J. Mol. Biol. 323, 613-628 (2002).

94.Melchjorsen, J., Pedersen, F.S., Mogensen, S. and Paludan, S.R: Herpes simplexvirus selectively induces expression of the CC chemokine RANTES/CCL5 inmacrophages through a mechanism dependent on PKR and ICP0. J.Virol. 76,2780-2788 (2002).

95.Aagaard, L., Mikkelsen, J.G., Warming, S., Duch, M. and. Pedersen, F.S.:Fv1-like restriction of N-tropic replication-competent murine leukemia virusesin mCAT-1 expressing human cells. J. Gen.Virol 82, 439-42 (2002).

96.Hansen, B.D., Duch, M., Hokland, P., Pedersen, F.S. and Hokland, M.:Quantitative evaluation of the murine B16 melanoma tumor model after genemarking with an EGFP/Neo expressing retroviral vector. In vivo 16, 167-174(2002).

97.Bachrach, E., Duch, M., Pelegrin, M., Dreja, H., Pedersen, F.S. and Piechaczyk,M.: In vivo infection by replication- competent MLV-based retroviral vectors.Methods Mol Med. 76: 343-52 (2003).

98. Bahrami,S., Jespersen, T., Pedersen, F.S. and Duch, M.: Mutational library analysis ofselected amino acids in the receptor binding domain of envelope of Akv murineleukaemia virus by conditionallv replication competent bi-cistronic retroviralvectors. Gene, 315:51-61 (2003).

99. Ma,S.L., Lovmand, J., Sørensen, A.B., Schmidt, J., and Pedersen, F.S.: Triple basepair changes within and adjacent to the conserved YY1 motif upstream of the U3enhancer repeats of SL3-3 murine leukemia virus cause a small, but significantshortening of latency of T-lymphoma induction. Virology, 313, 638-644 (2003).

100. Grunwald, T., Pedersen. F.S., Wagner, R.,and Überla, K.: Reducing lentiviral vector mobilization by primercomplementation and self-inactivation. J. Gene Med., 6, 147-154 (2004).

101.Aagaard, L., Rasmussen, S.V., Mikkelsen, J.G. and Pedersen, F.S.: Efficientreplication of full-length murine leukemia viruses modified at the dimerinitiation site regions. Virology, 318:360-370, (2004).

102.Mikkelsen, J.G., Rasmussen, S. V. and Pedersen, F.S: Complementarity-directedRNA dimer-linkage promotes retroviral recombination in vivo. Nucl. Acids Res.,32, 102-114 (2004).

103.Ulrich-Vinther M, Duch MR, Soballe K, O'Keefe RJ, Schwarz EM, Pedersen FS.: Invivo gene delivery to articular chondrocytes mediated by an adeno-associatedvirus vector. J Orthop Res. 22(4):726-34 (2004).

104.Duch, M., Carrasco, M.L., Jespersen, T., Hansen B.D, and Pedersen, F.S.:Transgene stability for three replication competent murine leukemia virusvectors. Gene, 329, 61-69 (2004).

105.Villesen P, Aagaard L, Wiuf C, Pedersen FS. Identification of endogenousretroviral reading frames in the human genome. Retrovirology. 2004 Oct11;1(1):32

106.Duch, M., Jespersen, T., Carrasco, M.L., Aagaard, L., and Pedersen, F.S.: AnRNA secondary structure bias for non-homologous reverse transcriptase mediateddeletions in vivo. Nucl. Acids Res., 32, 2039-2048 (2004).

107.Carrasco, M.L., Duch, M. and Pedersen, F.S.: The 5’ part of a tRNA as a templatein reverse-transcriptase-mediated retroviral recombination in vivo. J. Gen.Virol., 85, 1965-1969 (2004).

108.Wang, C.L., Hodgson, G., Malek, T., Pedersen, F.S., and Wabl. M.: A murineleukemia virus with Cre-LoxP excisible coding sequences allowingsuperinfection, transgene delivery, and generation of host genomic deletions.Retrovirology, 1, 5 (2004).

109.Bahrami S, Duch M, Pedersen FS.: Change of Tropism of SL3-2 Murine LeukemiaVirus, Using Random Mutational Libraries. J Virol. 78:9343-51 (2004).

110.Rasmussen, S.V., and Pedersen, F.S.: Complementarity between RNA dimerizationelements favors formation of functional heterozygous murine leukemia viruses.Virology 239, 440-453 (2004).

111.Sørensen, K.D., Quintanilla-Martinez, L., Kunder, S., Schmidt, J., andPedersen, F.S.: Mutation of all Runx (AML1/core) Sites in the Enhancer ofT-lymphomagenic SL3-3 MLV Unmasks a Significant Potential for Myeloid LeukemiaInduction and Favors Enhancer Evolution Towards Induction of Other DiseasePatterns. J. Virol., 78, 13216-13231 (2004).

112.Nielsen, A.A., Sørensen, A.B., Schmidt, J., and Pedersen, F.S.: Analysis ofwild type and mutant SL3-3 murine leukemia virus insertions in the c-mycpromoter during lymphomagenesis reveals target site hot-spots, virus dependentpatterns, and frequent error prone gap repair. J. Virol. 79. 76-78 (2005).

113.Ulrich-Vinther M, Schwarz EM, Pedersen FS, Søballe K, Andreassen TT: Genetherapy with human osteoprotegerin decreases callus remodeling with limitedeffects on biomechanical properties. Bone, 37:751-758 (2005).

114.Sørensen, K.D., Sørensen, A.B., Kremer, M., Quintanilla-Martinez, L., Schmidt,J., and Pedersen, F.S.: Distinct roles of enhancer nuclear factor 1 (NF1) sitesin plasmacytoma and osteopetrosis induction by Akv1-99 murine leukemia virus.Virology 334, 234-244 (2005).

115.Rasmussen MH, Sorensen AB, Morris DW, Dutra JC, Engelhard EK, Wang CL, SchmidtJ, Pedersen FS.: Tumor model-specific proviral insertional mutagenesis of theFos/Jdp2/Batf locus. Virology. 2005 337:353-64. (2005)

116.Glud S.Z., Sørensen, A.B., Andrulis, M., Wang, B., Kondo, E., Jessen, R.,Krenacs, L., Stelkovics, E., Wabl, M., Serfling, E., Palmetshofer, A.,Pedersen, F.S.: A Tumor Suppressor Function for NFATc3 in T CellLymphomagenesis by Murine Leukemia Virus; Blood 106:3546-52. (2005).

117.Aagaard, L., Villesen, P., Kjeldbjerg, A.L, and Pedersen, F.S.: The~30-million-year-old ERVPb1 envelope gene is evolutionarily conserved amonghominoids and Old World monkeys. Genomics, 86:685-91 (2005).

118.Basyuk, E., Boulon, S., Pedersen, F.S., Bertrand, E., Rasmussen, S.V.: Thepackaging signal of MLV is an integrated module that mediates intracellulartransport of genomic RNAs. J. Mol. Biol. 352:330-339 (2005).

119.Modin, C., Stranne, A.L., Foss, M., Duch, M., Justesen, J., Chevallier, J.,Andersen, L.K., Hemmersam, A.G., Pedersen, F.S., Besenbacher, F.: QCM-D studiesof attachment and differential spreading of pre-osteoblastic cells on Ta and Crsurfaces: Biomaterials, 27:1346-54 (2006).

120.Andersen, L.K., Contera, S.A., Justesen, J., Duch, M., Hansen, O., Chevallier,J., Foss, M., Pedersen, F.S., Besenbacher, F.: Cell Volume Increase In MurineMc3t3-E1 Pre-Osteoblasts Attaching Onto Biocompatible Tantalum Observed ByAtomic Force Microscopy. European Cells and Materials Journal. 10:61-68 (2005).

121.Stiehler, M., Duch, M., Mygind, T., Li, H., Ulrich-Vinther, M., Modin, M.,Baatrup, A., Lind , M., Pedersen, F.S. and Bünger, C.E.: Optimizing viral andnon-viral gene transfer methods for genetic modification of porcine mesenchymalstem cells. Adv Exp Med Biol. 2006;585:31-48.

122.Rasmussen, S.V., and Pedersen, F.S.: Co-localization of gammaretroviral RNAs attheir transcription site favours co-packaging. J. Gen. Virol. 87: 2279-2289(2006).

123.Ma, S.L., Sørensen, A.B., Kunder, S., Sørensen, K.D., Quintanilla-Martinez, L.,Morris, D.W., Schmidt, J., and Pedersen, F.S.: The Icsbp locus is a commonproviral insertion site in mature B-cell lymphomas/plasmacytomas induced byexogenous murine leukemia virus. Virology 352:306-18 (2006).

124.Lord, M.S., Modin, M., Foss, M., Duch, M., Simmons, A., Pedersen, F.S.,Milthorpe, B.K., and Besenbacher, F. Monitoring cell adhesion on tantalum andoxidised polystyrene using a quartz crystal microbalance with dissipation.Biomaterials. 27:4529-37. (2006).

125.Schyth, B.D., Lorenzen, N., and Pedersen, F.S.: Antiviral activity of smallinterfering RNAs: specificity testing using heterologous virus revealsinterferon-related effects overlooked by conventional mismatch controls.Virology. 349:134-41 (2006)

126.Tolstrup, M., Laursen, AL., Gerstoft, J., Pedersen, F.S., Ostergaard L., andDuch, M: Cysteine 138 mutation in HIV-1 Nef from patients with delayed diseaseprogression. Sex Health. 3:281-6. 2006

127.Martín-Hernández, J., Sørensen, A.B., Pedersen, F.S.: Non-identical patterns ofproviral insertions around host transcription units in lymphomas induced bydifferent strains of murine leukemia virus. Virology 353(1):193-9 (2006)

128.Tolstrup, M., Selzer-Plön, J., Laursen, A.L., Bertelsen, L., Gerstoft, J.,Duch, M., Pedersen, F.S., Ostergaard, L.: Full Fusion Competence Rescue of theEnfuvirtide Resistant HIV-1 gp41 Genotype (N43D) by a Naturally OccurringPolymorphism (E137K). AIDS, 21(4):519-521. (2007)

129.Sørensen K. D., Kunder, S., Quintanilla-Martinez, L., Sørensen, J., Schmidt,J., Pedersen, F.S.: Enhancer mutations of Akv murine leukemia virus inhibit theinduction of mature B-cell lymphomas and shift disease specificity towards themore differentiated plasma cell stage. Virology, 362, 179-191 (2007).

130.Bahrami, S., Duch, M.R., and Pedersen, F.S.: Ligand presentation on a syntheticflexible hinge in Moloney murine leukemia virus SU supports entry via aheterologous receptor. Virology, 363, 303-309 (2007).

131.Schyth, B.D., Lorenzen, N., and Pedersen, F.S: A High Through-Put In Vivo Modelfor Testing Delivery and Antiviral Effects of siRNAs in Vertebrates. Mol. Ther.15:1366-72 (2007).

132.Sørensen, A.B., Lund, A.H., Kunder, S., Quintanilla-Martinez, L., Schmidt, J.,Wang, B., Wabl, M., and Pedersen, F.S.: Impairment of alternative splice sitesdefining a novel exon within gag modifies the oncogenic properties of Akvmurine leukemia virus. Retrovirology, 2007 Jul 6;4(1):46.

133.Justesen, J., Lorentzen, M., Andersen, L.K., Hansen, O., Chevallier, J., Modin,C., Foss, M., Besenbacher, F., Duch, M., and Pedersen, F.S.: Spatial andtemporal changes in the morphology of preosteoblastic cells seeded onmicrostructured tantalum surfaces, J. Biomed. Mater. Res. A. 2009 Jun15;89(4):885-94.

134.Lord, M.S., Modin, C., Foss, M., Duch, M., Simmons, A., Pedersen, F.S.,Besenbacher, F., and Milthorp, B.K.: The influence of extracellular matrixremodelling during cell adhesion as monitored by the quartz crystalmicrobalance. Biomaterials, 2008 29(17):2581-7.

135.Hasemann, M.S., Damgaard, I., Schuster, M.B., Theilgaard-Mönch, K. Sørensen,A.B., Mrsic, A., Krugers, T., Ylstra, B., Pedersen, F.S., Nerlov, C., andPorse, T.B.: Mutation of C/EBP{alpha} predisposes to the development of myeloidleukemia in a retroviral insertional mutagenesis screen. Blood. 2008111(8):4309-21.

136.Ebbesen, M., Jensen, T.G., Andersen, S., and Pedersen, F.S.: EthicalPerspectives on RNA Interference Therapeutics. Int J Med Sci 2008 5(3):159-168.

137.Kjeldbjerg, A.L. , Villesen, P., Aagaard, L., and Pedersen, F.S.: Geneconversion and purifying selection of a placenta-specific ERV-V envelope geneduring simian evolution. BMC Evol Biol. 2008 Sep 30;8:266.

138.Matchkov, V.V., Larsen, P., Bouzinova, E.V., Rojek, A., Boedtkjer, D.M.B.,Golubinskaya, V., Pedersen, F.S., Aalkjær, C., Nilsson, H.: Bestrophin-3(Vitelloform Macular Dystrophy 2-Like 3 Protein) Is Essential for thecGMP-Dependent Calcium-Activated Chloride Conductance in Vascular Smooth MuscleCells. Circ Res. 2008 Oct 10;103(8):864-72.

139.Ejegod, D., Sørensen, K.D., Moßbrugger, I., Quintanilla-Martinez, L., Schmidt,J.,and Pedersen, F.S.: Control of pathogenicity and disease specificity of aT-lymphomagenic gammaretrovirus by E-box motifs but not by an overlappingglucocorticoid response element. J Virol. 2009 83:336-46

140.Dalsgaard, T., Moldt, B., Sharma, N., Wolf, G., Schmitz, A., Pedersen, F.S.,and Mikkelsen, J.G.: Shielding of Sleeping Beauty DNA transposon-deliveredtransgene cassettes by heterologous insulators in early embryonal cells MolTher. 2009 17:121-30.

141.Lovmand, J., Justesen, J., Foss, M., Lauridsen, R.H., Lovmand, M., Modin, C.,Besenbacher, F., Pedersen, F.S., and Duch, M.: The use of combinatorialtopographical libraries for the screening of enhanced osteogenic expression andmineralization. Biomaterials, 2009 30:2015-22.

142.Liu, J., Sørensen , A.B., Wang, B., Wabl, M, Nielsen , A.L., and Pedersen, F.S.: Identification of novel Bach2 transcripts and protein isoforms throughtagging analysis of retroviral integrations in B-cell lymphomas. BMC MolecularBiology 2009, 10:2.

143.Nielsen, A.A., Kjartansdóttir, K.R., Rasmussen, M.H., Sørensen, A.B., Wang, B.,Wabl, M. and Pedersen, F.S.: Activation of the brain-specific neurogranin genein murine T-cell lymphomas by proviral insertional mutagenesis. Gene 442 55–62(2009).

144.Rasmussen, M.H., Wang, B., Wabl, M., Nielsen, A.L., and Pedersen, F.S.:Activation of alternative Jdp2 promoters and functional protein isoforms inT-cell lymphomas by retroviral insertion mutagenesis, Nucl. Acids Res.,37:4657-71 (2009).

145.Dabrowska, M.J., Dybkær, K., Johnsen, H.E., Wang, B., Wabl, M., Pedersen, F.S.:Loss of microRNA-targets in the 3'-untranslated region as a mechanism ofretroviral insertional activation of Growth Factor Independence 1. J. Virol.83(16):8051-61. (2009).

146. Markert,L.D., Lovmand, J., Foss, M., Lauridsen, R.H., Lovmand, M., Füchtbauer, E.M.,Füchtbauer, A., Wertz, K., Besenbacher, F., Pedersen, F.S., and Duch, M.:Identification of distinct topographical surface microstructures favoringeither undifferentiated expansion or differentiation of murine embryonic stemcells. Stem Cells Dev. 18:1331-42 (2009).

147.Jørgensen JM, Sørensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ,Tainola T, Sørensen AB, Pedersen FS, D'Amore F. Expression level, tissue distributionpattern, and prognostic impact of vascular endothelial growth factors VEGF andVEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes ofnon-Hodgkin lymphomas. Leuk Lymphoma 13:1-14 (2009).

148.Jensen, T.H.L., Dolatshahi-Pirouz, A., Foss, M., Baas, J., Lovmand, J., Duch,M., Pedersen, F.S., Kassem, M., Bünger, C.E., Søballe, K., Besenbacher, F.:Interaction of human mesenchymal stem cells with osteopontin coatedhydroxyapatite surfaces. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):186-93.

149.Kharytonchyk, S. and Pedersen F.S.: A unique thermostable dimer linkagestructure of RD114 gammaretroviral. RNA. 2010 Mar;16(3):572-84. Epub 2010 Jan14.

150.Bahrami, S., Ejegod, D., Sørensen, K.D. and Pedersen, F.S.: Coupling of receptorinterference and a host-dependent post-binding entry deficiency in agammaretroviral envelope protein. Retrovirology 2010, 7:9.

151.Rasmussen, M.H., Ballarín-González, B, Liu, J., Lassen, L.B., Füchtbauer, A.,Füchtbauer, E.M., Nielsen, A.L., Pedersen, F.S.: Antisense transcription ingammaretroviruses as a mechanism of insertional activation of host genes. JVirol. 2010 Apr;84(8):3780-8. Epub 2010 Feb 3.

152.Pyrz, M., Wang, B., Wabl, M., and Pedersen, F.S.: A retroviral mutagenesisscreen identifies Cd74 as a common insertion site in murine B-lymphomas andreveals the existence of a novel IFNgamma-inducible Cd74 isoform. MolecularCancer 9:86 (2010).

153.Kolind K, Dolatshahi-Pirouz A, Lovmand J, Pedersen FS, Foss M, Besenbacher F. Acombinatorial screening of human fibroblast responses on micro-structuredsurfaces. Biomaterials. 31:9182-9191 (2010) .

154.Maric R, Pedersen FS, Kjeldbjerg A, Moeller-Larsen A, Bahrami S, Brudek T,Petersen T, Christensen T. Absence of xenotropic murine leukaemia virus-relatedvirus in Danish patients with multiple sclerosis. J Clin Virol. 2010 Sep 7.[Epub ahead of print] PubMed PMID: 20829105.

155.Nexø BA, Christensen T, Frederiksen J, Møller-Larsen A, Oturai AB, Villesen P,Hansen B, Nissen KK, Laska MJ, Petersen TS, Bonnesen S, Hedemand A, Wu T, WangX, Zhang X, Brudek T, Maric R, Søndergaard HB, Sellebjerg F, Brusgaard K,Kjeldbjerg AL, Rasmussen HB, Nielsen AL, Nyegaard M, Petersen T, Børglum AD,Pedersen FS. The Etiology of Multiple Sclerosis: Genetic Evidence for theInvolvement of the Human Endogenous Retrovirus HERV-Fc1. PLoS One. 2011 Feb2;6(2):e16652

156.Kelsen J, Dige A, Schwindt H, D’Amore F, Pedersen FS, Agnholt J, ChristensenLA, Dahlerup JF, Hvas CL: Infliximab Induces Clonal Expansion of gamma-delta-TCells in Crohn’s Disease: a Predictor of Lymphoma Risk? 2011 PloS One March31;6(3):e17890.

157. Broegger T, Jacobsen JC, Secher Dam V, BoedtkjerDM, Kold-Petersen H, Pedersen FS, Aalkjaer C, Matchkov VV. Bestrophin is important for the rhythmic butnot the tonic contraction in rat mesenteric small arteries. Cardiovasc Res.2011 Sep 1;91(4):685-93.

158.Kirkegaard, T., Wheatley, A.K., Melchjorsen, J., Bahrami, S., Pedersen, F.S.,Center, R.J., Purcell, D.F.J., Ostergaard, L.; Duch, M., Tolstrup, M.:Induction of humoral and cellular immune responses against the HIV-1 envelopeprotein using γ-retroviral virus-like particles. Virol J. 2011 Aug 1;8(1):381.

159.Füchtbauer A, Lassen LB, Jensen AB, Howard J, Quiroga Ade S, Warming S,Sørensen AB, Pedersen FS, Füchtbauer EM. Septin9 is involved in septin filamentformation and cellular stability. Biol Chem. 2011 Aug;392(8-9):769-77.

160.Aagaard L, Bjerregaard B, Kjeldbjerg AL, Pedersen FS, Larsson LI, Rossi JJ.:Silencing of endogenous envelope genes in human choriocarcinoma cells showsthat envPb1 is involved in heterotypic cell fusions J Gen Virol. 2012 Aug;93(Pt8):1696-9.

161.Lassen LB, Ballarín-González B, Schmitz A, Füchtbauer A, *Pedersen FS,*Füchtbauer, EM. (2012) Nras Overexpression Results in Granulocytosis, T-CellExpansion and Early Lethality in Mice. PLoS ONE 7(8): e42216.doi:10.1371/journal.pone.0042216

162.Bahrami S, Pagh K, Ejegod D, Duch M, Tolstrup M, *Pedersen FS. Construction ofa gammaretrovirus with a novel tropism and wild type replication kineticscapable of using human APJ as entry receptor. J Virol. 2012 86:10621-10627.

163.Jensen SMR, Schmitz A, Pedersen FS, Kjems J, Bramsen JB (2012) FunctionalSelection of shRNA Loops from Randomized Retroviral Libraries. PLoS ONE 7(8):e43095. doi:10.1371/journal.pone.0043095

164.Nissen, KK, Laska, MJ, Hansen, B, Pedersen, FS, Nexø, BA (2012). No additionalcopies of HERV-Fc1 in the germ line of multiple sclerosis patients. Virol. J.9:188.

165.Ballarín-González B, Lassen LB, Jessen R, Füchtbauer A, Füchtbauer E-M,Pedersen, F.S. (2013) Deregulated Nras Expression in Knock-In Animals Harboringa Gammaretroviral Long Terminal Repeat at the Nras/Csde1 Locus. PLoS ONE 8(2):e56029. doi:10.1371/journal.pone.0056029

166.Wolf, G., Nielsen, A.L., Mikkelsen, J.G., Pedersen, F.S.: Epigenetic markingand repression of porcine endogenous retroviruses. J. Gen. Virol. 94:960-970(2013).

167.Lassen, LB, Füchtbauer, A, Schmitz, A; Sørensen, AB, Pedersen, FS, Füchtbauer,EM: Septin9 is involved in T-cell development and CD8+ T-cell homeostasis. Celland Tissue Research, . Cell Tissue Res. 2013 Jun;352(3):695-705.

168.Dabrowska, MJ. Ejegod, D, Lassen, LB, Johnsen, HE, Wabl, M, Pedersen, FS, andDybkær, K: Gene expression profiling of murine T-cell lymphoblastic lymphomaidentifies deregulation of S-phase initiating genes Leuk Res. doi:pii:S0145-2126(13)00122-7. (2013).

169.Andersen SS, Hvid M, Pedersen FS, Deleuran B. Proximity ligation assay combinedwith flow cytometry is a powerful tool for the detection of cytokine receptordimerization. Cytokine. doi:pii: S1043-4666(13)00207-X. (2013).

170.Nexø BA, Hansen B, Nissen KK, Gundestrup L, Terkelsen T, Villesen P, Bahrami S,Petersen T, Pedersen FS, Laska MJ. Restriction genes for retroviruses influencethe risk of multiple sclerosis. PLoS One. 2013 Sep 16;8(9):e7406.

171.Tolstrup, M., Johansen, C., Toft, L., Pedersen, FS., Funding, A., Bahrami, S.,Iversen, L., Østergaard, L., Duch, M. Anti-inflammatory effect of a retrovirus-derivedimmunosuppressive peptide in mouse models. BMC Immunol. 2013 Nov 18;14(1):51.

172.Kolind, K. , Kraft, D.C., Bøggild, T., Duch, M.R., Lovmand, J.,Pedersen, F.S.,Bindslev, D.A., Bünger, C.E., Foss, M., Besenbacher, F.:Control of proliferationand osteogenic differentiation of human dental pulpderived stem cells bydistinct surface structures. Acta Biomater. 2014;10:641-50.

173.Sokol,M., Wabl, M., Rius Ruiz, I. and Pedersen, F.S. NovelPrinciples ofGamma-Retroviral Insertional Transcription Activation in MurineLeukemiaVirus-induced End-stage Tumors. Retrovirology 11:36, 2014.

174.Wolf, G., Yang, P., Füchtbauer,A.C., Füchtbauer, E.M, Silva, A.M., Park, C.,Wu, W., Nielsen, A.L., Pedersen,F.S. and Macfarlan, T.S.. The KRAB zinkfingerprotein ZFP809 is required to initiate epigenetic silencing ofendogenousretroviruses. Genes Dev. 2015 Mar 1;29(5):538-54.

175.Kajhøj T.Q. Mogens Duch, Pedersen,F.S., Løvschall, H., Füchtbauer, E.M. Test ofcritical steps towards a combinedcell and gene therapy approach for thetreatment of Duchenne musculardystrophy. J Mol Genet Med (2015) 9:160.doi:10.4172/1747-0862.1000160. 176. Sokol M, Jessen KM, Pedersen FS. Humanendogenous retrovirusessustain complex and cooperative regulation ofgene-containing loci andunannotated megabase-sized regions. Retrovirology. 2015Apr 17;12:32.

177.Schyth BD, Bela-Ong DB, Jalali SA,Kristensen LB, Einer-Jensen K, Pedersen FS,Lorenzen N. Two Virus-InducedMicroRNAs Known Only from Teleost Fishes AreOrthologues of MicroRNAs Involvedin Cell Cycle Control in Humans. PLoS One.2015 Jul 24;10(7):e0132434. doi:10.1371/journal.pone.0132434.

178.Hede, MS, Okorie, PN, Fruekilde, SK, Fjelstrup, S, Thomsen, J,Franch, O,Tesauro, C, Bugge, MT, Christiansen, M, Picot, S, Lötsch, F,Mombo-Ngoma, G,Mischlinger, J, Adegnika, A, Pedersen, FS, Ho,YP, Petersen, E, Stougaard, M,Amharter, M, RuthKnudsen, BR: Refined method fordroplet-microfluidics enableddetection of Plasmodium falciparum encodedtopoisomerase I in blood from malariapatients. Micromachines, Vol. 6, Nr. 10,05.10.2015, s. 1505-1513.

179.Sokol, M., Jessen, .K.M., Pedersen, F.S.: Utility of next-generationRNA-sequencingin identifying chimeric transcription involving human endogenousretroviruses.APMIS, 2016 Jan;124(1-2):127-39.

180.Bahrami, S. , Laska, M.J., Pedersen, F.S. and Duch, M.: Immunesuppressiveactivity of the influenza fusion peptide. Virus Res. 2016 Jan4;211:126-32.

181.Friis KP, Iturrioz X, Thomsen J, Alvear-Perez R,Bahrami S, Llorens-Cortes C andPedersen FS: Directed molecular evolution of anengineered gammaretroviralenvelope protein with dual receptor use shows stablemaintenance of both receptorspecificities. J Virol. 2015 Nov 25;90(3):1647-56.

182.Wang J, Liu J, Thomsen J, Selnihhin D, Hede MS, Kirsebom FC, Franch O,Fjelstrup S, Stougaard M, Ho YP, Pedersen FS, Knudsen BR. Novel DNA sensorsystem for highly jelstrup S, Stougaard M, Ho YP, Pedersen FS, KnudsenBR.sensitive and quantitative retrovirus detection using virus encodedintegraseas a biomarker. Nanoscale. 2017 Jan 7;9(1): 440- 448. doi 10.1039/c6nr07428f.PubMed PMID: 27934981.039/c6nr07428f. PubMed PMID: 27934981.


183. Fjelstrup S, Andersen MB, Thomsen J, Wang J, Stougaard M, Pedersen FS, Ho YP, Hede MS, Knudsen BR. The Effects of Dithiothreitol on DNA. Sensors (Basel). 2017 May 24;17(6). pii: E1201. doi: 10.3390/s17061201. PubMed PMID: 28538659; PubMed Central PMCID: PMC5492665.

 

184. Møller AMJ, Füchtbauer EM, Brüel A, Andersen TL, Borggaard XG, Pavlos NJ,

Thomsen JS, Pedersen FS, Delaisse JM, Søe K. Septins are critical regulators of

osteoclastic bone resorption. Sci Rep. 2018 Aug 29;8(1):13016. doi:

10.1038/s41598-018-31159-1. PubMed PMID: 30158637; PubMed Central PMCID:

PMC6115361.

 

185. Franch O, Han X, Marcussen LB, Givskov A, Andersen MB, Godbole AA, Harmsen C, Nørskov-Lauritsen N, Thomsen J, Pedersen FS, Wang Y, Shi D, Wejse C, Pødenphant L, Nagaraja V, Bertl J, Stougaard M, Ho YP, Hede MS, Labouriau R, Knudsen BR. A new DNA sensor system for specific and quantitative detection of mycobacteria. Nanoscale. 2018 Dec 17. doi: 10.1039/c8nr07850e. [Epub ahead of print] PubMed PMID: 30556557.


Peer-reviewedsurvey papers, book chapters, misc:

186.Lund, E., Pedersen, F.S. & Kjeldgaard, N.O.: The synthesis of magic spots-A functional role for uncharged tRNA? In: Ribosomes and RNA metabolism.Publishing House of the Slovak Academy of Sciences, Bratislava, pp. 307-319,Bratislava, 1973.

187.Pedersen, F.S.: Stringent factor. In: Control of ribosome synthesis. AlfredBenzon Symposium IX (Maaløe, O. & Kjeldgaard, N.O., eds.), Munksgaard, pp.419-426, Copenhagen 1976.

188.Haseltine, W.A., Kleid, D.G. & Pedersen, F.S. Analysis of RNA tumor virusgenomes. In: Advances in comparative leukemia research (Bentvelzen et al.,eds.), Elsevier/North Holland Biomedical Press, pp. 437-442, Amsterdam, 1978.

189.Haseltine, W.A., Pedersen, F.S., Sahagan, B.G., Rosenberg, Z.F. & Kozlov,J. Comparative analysis of RNA tumor virus genomes. In: Modern trends in humanleukemia vol. III (R. Neth and R. Gallo eds.), Springer-Verlag, pp. 529-552,Berlin 1979.

190.Pedersen, F.S. & Haseltine, W.A.: A micromethod for characterization ofhigh molecular weight RNA. Methods in Enzymology 65, 680-687 (1980).

191.Clements, J.E., Pedersen, F.S., Narayan, O. & Haseltine, W.A.: Mutation asa mechanism for escape for immune suppression: The Visna virus example. In:Viruses in naturally occurring cancers, Cold Spring Harbor Conferences on cellproliferation, volume 7, pp. 953-967, Cold Spring Harbor Laboratory, 1980.

192.Clements, J.E., D'Antonio, N., Narayan, O., Pedersen, F.S. & Haseltine,W.A.:Antigenic variation of Visna virus. In: Animal virus genetics, ICN-UCLASymposia on Molecular and Cellular Biology (B. Fields, R. Jaenisch, C.F. Fox,eds), Vol. XIII, Acad. Press, New York, 1980.

193.Rosenberg, Z.F., Pedersen, F.S. & Haseltine, W.A.: RNaseT1 fingerprintanalysis of Feline leukemia virus, subgroup A, B, and C. In: Proceedings of theThird International Feline Leukemia Virus Meeting (Hardy, J., Essex, M. &McClelland, R.J., eds.) pp. 355-359, Elsevier/North Holland, 1980.

194.Merregaert, J., Michiels, L., Pedersen, F.S., de Saint-Georges, L., Janowski,M. & Maisin, J.R.: Isolement et characterization de rétrovirus explimésdans les ostéosarcomes murins induit par le 90Sr. C. Séanc. Soc. Biol. 178,171-182 (1984).

195.Erfle, V., Schmidt, J., Leib-Mösch, C., Pedersen, F.S., Luz, A.: Einfluss derGenomstruktur von Retroviren auf die Entwicklung von Knochentumoren. In Berichtdes 16. Kongresses der Deutchen Veterinärmedizinischen Gesellschaft, pp118-125, Verl. Parey, Berlin, Hamburg 1985.
196.Kjeldgaard, NO, Pedersen, FS and Jørgensen, P: Grundforskning og gensplejsning./ af Niels Ole Kjeldgaard, Finn Skou Pedersen & Poul Jørgensen. In“Gensplejsning og forskning” Mogens Dahl ed. Impressum Kbh. : Planlægningsrådetfor Forskningen : Forskningssekretariatet, 1986.

197.Pedersen, F.S., Etzerodt, M., Lovmand, S., Dai, H.Y., Bækgaard, A.J., Sørensen,J., Jørgensen, P., Kjeldgaard, N.O., Schmidt, J., Leib-Mösch, C., Luz, A. &Erfle, V.: Transcriptional control and oncogenicity of murine leukemia viruses.In Viral Carcinogenesis, Alfred Benzon Symposium 24 ( N.O. Kjeldgaard & J.Forchhammer, eds.), Munksgaard pp 17-35, Copenhagen 1987.

198.Jensen, N.A., Jørgensen, P., Kjeldgaard, N.O. & Pedersen, F.S.: Expressionof BPV1 late genes in cultured cells using retroviral vectors. Cancer Cells 5(B.M. Steinberg; J.L. Brandsma; L.B.; L.B. Taichman, eds.), pp. 135-137 ColdSpring Harbor Laboratory, Cold Spring Harbor, N.Y., USA 1987.

199.Kjeldgaard, N.O., Bækgaard, A.J., Dai, H.Y., Etzerodt, M., Jørgensen, P.,Lovmand, S., Olsen, H.S., & Pedersen, F.S.: Transcriptional control byretroviral LTR regions. In Evolutionary Tinkering in Gene Expression. NATOAdvanced Summer Institute Series (M. Grunberg-Manago ed.), pp 82-94, PlenumPublishing Corp., New York, USA, 1989.

200.Pallisgaard, N., Pedersen, F.S., Kjeldgaard, N.O., and Jørgensen, P.: Cloningof cDNAs for proteins binding to the MuLV enhancer region. In Gene Regulation,Oncogenesis, and AIDS (T.S. Papas, ed.), pp. 87-94, Portfolio PublishingCompany, The Woodlands, Texas, 1990.

201.Pedersen, F.S., Paludan, K., Dai, H.Y., Duch, M., Jørgensen, P., Kjeldgaard,N.O., Hallberg, B., Grundström, T., Schmidt, J., and Luz, A. The murineleukemia virus LTR in oncogenesis: Effect of point mutations and integrationsites. Rad. Environ. Biophys. 30, 195-198 (1991).

202.Lovmand, J., Lund, A.H. and Pedersen, F.S.: Growth and production of murineleukemia viruses. In Cell Biology: A laboratory Handbook (J.E. Celis, Ed.) pp.500-506, Academic Press, San Diego, U.S.A., (1994).

203.Lund, A.H., Duch, M. and Pedersen, F.S.: Transcriptional silencing ofretroviral vectors. J. Biomed. Sci. 3, 365-378 (1996).

204.Pedersen, F.S. and Duch, M.: Retroviral vector library technology for targetingand identifying components of intracellular pathways in mammalian cells.Bioforum International. 3, 137-139 (1999).

205.Sørensen, A.B., Duch, M., and Pedersen, F.S.: Isolation of unknown flanking DNAby a simple two-step polymerase chain reaction method. DYNALogue (periodicalpublication of DYNAL A/S, Norway), issue 3, 2-3 (1999).

206.Pedersen, F. S. and Duch, M.: Retroviral replication. In Encyclopedia of LifeSciences. Nature Publishing Group, Macmillan Reference Limited.(2001).www.els.net

207.Mikkelsen, J.G. and Pedersen, F.S.: Genetic reassortment and patch-repair byrecombination in retroviruses. J. Biomed. Sci. 7, 77- 99 (2000).

208Pedersen, F. S. and Duch, M.: Retroviruses in human gene therapy. InEncyclopedia of Life Sciences. Nature Publishing Group, Macmillan ReferenceLimited. (2001).www.els.net

209.Pedersen, F.S. and Duch, M.: Replication competent retroviral vectors. BioforumInternational, 6, 100-104 (2002).

210.Hansen, A.C. and Pedersen, F.S.: Safety features of retroviral vectors.Curr.Opin.Mol.Ther., 4, 324-333 (2002).

211.Tolstrup, M., Østergaard, L., Laursen, AL., Pedersen, F.S., and Duch, M.:HIV/SIV escape from immune surveillance: Focus on nef. Curr HIV Res. 2, 141-51(2004).

212.Nielsen M.H., Pedersen, F.S., Kjems, J.: Molecular strategies to inhibit HIV-1replication. Retrovirology. 2005 Feb 16;2(1):10.

213.Pedersen, F.S. and Sørensen, A.B.: Pathogenesis of oncoviral infections. Pp.237-268 In: Retroviruses: Molecular Microbiology and Genomics (R. Kurth and N.Bannert, eds.), Caister Academic Press, Norfolk, UK (2010). ISBN:978-1-904455-55-4

214.Bahrami, S. and Pedersen, F.S.: Viral technology for delivery of nucleicacids.pp. 93-112. In: Delivery Technologies for Biopharmaceuticals: Peptides,Proteins, Nucleic Acids and Vaccines. (L. Jørgensen and H. Mørck Nielsen, eds.)John Wiley & Sons (2009). ISBN: 978-0-470-72338-8

215.Ebbesen M, Bek T, Pedersen FS, Jensen TG. [Unspecific effects of certain siRNAmolecules used in the treatment of age related macular degeneration]. UgeskrLaeger. 2010 Sep 6;172(36):2457-9. Danish. PubMed PMID: 20825735.

216.Kjeldbjerg, A.L., Bahrami, S., and Pedersen, F.S.: Retroviruses and cellfusions: overview. Pp. 11-39 In: Cell Fusions: Regulation and Control. (LILarsson ed.). Springer Verlag, (2011). ISBN 978-90-481-9771-2.

217.Kjeldsen MK, Dybkaer K, Liu J, Pedersen FS . BACH2 (BTB and CNC homology 1,basic leucine zipper transcription factor 2). Atlas Genet Cytogenet OncolHaematol. January 2010 .
URL :http://AtlasGeneticsOncology.org/Genes/BACH2ID741ch6q15.html

218.Pedersen, F.S., Pyrz, M., and Duch, M. (April 2011) Retroviral Replication. In:Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester.DOI: 10.1002/9780470015902.a0000430.pub3

219. Markert,L., Lovmand, J., Duch, M., and Pedersen, F.S.: Topographically and chemicallymodified surfaces for expansion or differentiation of embryonic stem cells. In“Methodological Advances in the Culture, Manipulation and Utilization ofEmbryonic Stem Cells for Basic and Practical Applications”. InTech - OpenAccess Publisher http://www.intechweb.org/ (2011).

220.Ebbesen, M, Pedersen, FS, Andersen, S, Jensen, TG: Ethical perspectives on stemcell-based cellular therapies for neurodegenerative diseases. J. Cell Sci.Ther. S3:003 (2012). doi: 10.4172/2157-7013.S3-003

221.Nissen, K.K., Laska, M.J., Hansen, B., Terkelsen, T., Bahrami, S., Villesen,P., Petersen, T., Pedersen, F.S. and Bjørn Nexø. Endogenous retroviruses andmultiple sclerosis - new pieces to the puzzle. BMC Neurology, BMC Neurol.13(1):111. (2013).

222.Pedersen, F.S., Bahrami, S., Duch, M.R.: Retroviruses in Human GeneTherapy.Encyclopedia of Life Sciences. Chichester : Wiley, 2014.http://www.els.net;DOI:10.1002/9780470015902.a0001002.pub3.

223.Ebbesen, M., Andersen, S., and Pedersen. F.S.: A conceptualframework for the ethics of synthetic biology. Academic Quarter, Vol. 12, 2015,. 203-223.

 

224. Pedersen, Finn S and Mikkelsen, Jacob G (September 2018) Retroviruses in Human Gene Therapy. In: eLS. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0001002.pub4




Published patents (from Derwent Innovation Index):

225. WO9527063-A; EP755448-A; DE4411718-A1; WO9527063-A2; AU9523050-A; WO9527063-A3; EP755448-A1. RFB-14 retrovirus genome - and prodn. of osteo-inductive proteins. SCHMIDT J; GIMBEL W; STRAUSS P; ERFLE V; PEDERSEN F S; PEDERSEN L; OESTERGAARD M; OSTERGAARD M

226. EP832207-A; WO9638553-A; EP1041143-A; KR99022157-U; WO9638553-A1; AU9658933-A; EP832207-A1; AU699568-B; JP11505724-W; KR99022157-A; EP832207-B1; EP1041143-A2; DE69610310-E; ES2151167-T3; US2001053523-A1; US2003082514-A1. Identifying biologically active peptide(s) and nucleic acids - by transducing vectors contg. random DNA sequences into cells and screening for altered phenotypic trait. JENSEN M R; PEDERSEN F S; MOURITSEN S; HINDERSSON P; DUCH M; SORENSEN M S; DALUM I; LUND A H; SOERENSEN M S; MOURITZEN S

227. US5866411-A. Murine leukaemia virus transfer vector - with modified primer binding site requiring artificial primer. LUND A H; JORGENSEN P; LOVMAND J; PEDERSEN F S; DUCH M

228. US5886166-A. Murine leukaemia virus retroviral vector - whose transfer is dependent on the presence of specific tRNA-like primer. PEDERSEN F S; JORGENSEN P; LOVMAND J; LUND A H; DUCH M

229. US6037172-A. Retroviral vector for gene transfer, useful as antiviral agent, has a primer binding site modified to prevent base pairing with natural transfer RNA. LUND A H; LOVMAND J; PEDERSEN F S; DUCH M; JORGENSEN P

230. US6107478-A. New modified tRNA primer for reverse transcribing a retroviral transfer vector comprising a primer binding site modified to a sequence which does not allow strong base pairing with the 3' end in any occurring tRNA. DUCH M; LOVMAND J; LUND A H; PEDERSEN F S; JORGENSEN P

231. WO200066758-A; EP1173597-A; WO200066758-A1; AU200045598-A; EP1173597-A1; JP2002542834-W; US7056730-B2. Retroviral vector for gene therapy, comprises a gene of therapeutic use or of viral origin under the translational control of an internal ribosome entry site (IRES). PEDERSEN F S; JESPERSON T; DUCH M; PEDERSEN F S

232. WO200292825-A; WO200292825-A2; EP1399574-A2; AU2002316788-A1; JP2004533827-W; US2004248083-A1; AU2002316788-A8; WO200292825-A3. New retroviral vector system comprising a retroviral vector having modified heterologous or synthetic dimerization sequence and a transcript of different retrovirus useful for preparing a composition or medicament for gene therapy. MIKKELSEN J G; RASMUSSEN S V; DUCH M; PEDERSEN F S; AAGAARD L

233. WO2003006688-A; WO2003006688-A2; AU2002313491-A1; AU2002313491-A8; WO2003006688-A3. Screening drug candidates which can modulate Gnas proteins for treating lymphoma or leukemia, comprises contacting a cell expressing a GNAS gene with a candidate drug and determining the effect of the drug on gene expression. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M

234. WO2003006689-A; WO2003006689-A2; EP1419276-A2; AU2002328896-A1; US2007092873-A1; AU2002328896-B2; WO2003006689-A3; AU2008201683-A1.Screening drug candidates for producing a medicament for treating lymphoma by providing a cell that expresses a HIPK1 gene and determining the effect of the drug candidate on the expression of the HIPK1 gene. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M; BAYMIEV A K; CHEMERIS A V; CHEMERIS D A; KORPELA T K; USANOV N G; VAKHITOV V A

235. WO2003027295-A; WO2003027320-A; WO2003027321-A; WO2003043565-A; WO2003027276-A; US2002115058-A1; WO2003027276-A2; WO2003027295-A2; WO2003027320-A2; WO2003027321-A2; WO2003043565-A2; AU2002364889-A1; AU2002329000-A1; AU2002337442-A1; AU2002337442-A8; WO2003027321-A3; WO2003027295-A3; WO2003027320-A3; WO2003043565-A3; WO2003027276-A3

Novel recombinant lymphoma associated protein, referred as Pik3r1, useful for prognosis, diagnosis and treatment of lymphoma, leukemia, wounds and inflammation, and for inhibiting tumor growth. PEDERSEN F S; SOERENSEN A B; NIELSEN A A; SORENSEN A B; HERNANDEZ J M; MOVING H

236. US2003044803-A1. New recombinant Janus family of tyrosine kinases, e.g. JAK1 protein, useful in diagnosis or prognosis of lymphoma, in screening for modulators, for antibody generation, or as therapeutic agents. PEDERSEN F S; SOERENSEN A B; MARTIN J H

237. US2003157718-A1. New retroviral vector expressing a gene under the translational control of an internal ribosomal entry site, useful for making a medicament for use in gene therapy and for efficient translation of the gene. PEDERSEN F S; JESPERSON T; DUCH M

238. US2003224460-A1; AU2002330713-A1; AU2002330715-A1; AU2002364889-A8; AU2002330713-A8; AU2002329000-A8. Novel recombinant protein comprising lymphoma associated protein, useful in treating lymphoma and leukemia. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M; NIELSEN A A; MOVING H; SOERENSEN A B

239. WO200224867-A; WO200224867-A2; AU200191217-A; US2002164576-A1; US2003077590-A1; AU2001291217-A8; WO200224867-A3. Novel recombinant lymphoma associated protein (LAP) such as Pik3r1, GNAS, JAK1, Neurogranin, Nfr2 proteins, useful for identifying inhibitors of LAP activity that are used for treating lymphoma. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M; NIELSEN A A; MOVING H O; SOERENSEN A B; MOVING H.

240. WO2003097674-A1; AU2003223938-A1; EP1511767-A1; US2006084791-A1; EP1511767-B1; DE60328491-E. New purified murine retroviral envelope polypeptide that is capable of mediating infection of a cell derived from Mus musculus, useful in gene discovery of a cancer related gene. PEDERSEN F S; DUCH M R; BAHRAMI S;

241. WO2006114098-A2; EP1874367-A2; IN200704673-P4; CN101193666-A; US2008208351-A1; EP1874367-B1; WO2006114098-A3. Biocompatible material for use in e.g. cell culture, has nano or micrometer scale topographical structure comprising several features of predetermined dimension, arranged in regular pattern. BESENBACHER F; DUCH M R; FOSS M; PEDERSEN F S; JUSTESEN J H F; ANDERSEN L K; CROVATO T E L; MARKERT L; DUCH M

242. WO2006114097-A2; EP1875234-A2; CN101180538-A; US2008227656-A1; EP1875234-B1; WO2006114097-A3; CN101180538-B; IN200704674-P4. Microenvironment testing biosurface structure for cultivation of cells, has set of tester areas each including surface topology whose features are defined on micro- or nanometer scale, and bioactive compound deposited in surface. BESENBACHER F; DUCH M R; FOSS M; PEDERSEN F S;

243. US2007098728-A1. Treating lymphoma or leukemia in a patient comprises modulating the level of an expression product of a gene selected from PI3KR1, GNAS, NESP5, JAK1, neurogranin, HIPK1, or Nrf2. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M; NIELSEN A A; MOVING H

244. US2007059724-A1. Diagnosing cancer in a patient comprises detecting the presence of differential expression of HIPK1 in a patient sample, where presence of differential expression of HIPK1 in the sample is indicative of a patient who has cancer. PEDERSEN F S; SORENSEN A B; HERNANDEZ J M; NIELSEN A A; MOVING H

245. WO2007107156-A2; WO2007107156-A3; EP2004677-A2; US2009324553-A1. New chimeric viral envelope polypeptide comprise a gamma retrovirus envelope polypeptide, and a receptor-binding domain of a second, different viral envelope polypeptide, useful for treating, preventing, or reducing a viral infection. PEDERSEN F S; BAHRAMI S; DUCH M R; OSTERGAARD L; TOLSTRUP M;

246. WO2008151633-A2; WO2008151633-A3. New mammalian expression vector comprises a heterologous nucleic acid sequence encoding a lentiviral envelope polypeptide or its fragment, useful as vaccine for treating, ameliorating, and/or preventing HIV infection and/or AIDS. TOLSTRUP M; PEDERSEN F S; OSTERGAARD L; DUCH M R; NIELSEN T K

247. WO2009150051-A2; WO2009150051-A9; WO2009150051-A3; AU2009256776-A1; EP2291510-A2; CA2725251-A1; KR2011046397-A; US2011160869-A1; CN102232109-A; JP2012527866-W; US8470600-B2. Use of cell or tissue culture container for promoting growth of undifferentiated pluripotent mammalian embryonic stem cells, where the container has a surface for exposure to a culture during use. BESENBACHER F; DUCH M R; FOSS M; LOVMAND J; MARKERT L; PEDERSEN F S; FUECHTBAUER A C; FUECHTBAUER E M

248. WO2010022740-A2; WO2010022740-A3; CA2735278-A1; EP2331565-A2; US2011305749-A1. New HIV-1 envelope polypeptide comprising an amino acid sequence useful as vaccine to treat HIV infection and/or AIDS. BAHRAMI S; DUCH M R; FREDSTED P V; OSTERGAARD L J; PEDERSEN F S; TOLSTRUP M; WIUF C; OESTERGAARD L J

249. WO2010034314-A1. New multifunctional molecule initiating two strand DNA synthesis of retroviral RNA genome and having first part with nucleotide sequence complementary to primer binding site, and second part having genetic element, used to treat e.g. cancer. BAHRAMI S; PEDERSEN F S

250. WO2011077093-A1; EP2516459-A1; US2013108653-A1. New molecule comprising first part of first virus binding moiety that binds to first viral protein, and second part of second virus binding moiety that binds to second viral protein, useful for treating AIDS.BAHRAMI S; PEDERSEN F S; RYTTERGMRD M D; TOLSTRUP M; OSTERGAARD L J

251. WO2010051820-A1. Treating, preventing or ameliorating clinicalcondition comprises bringing non-identical nucleic acid species into contactwith the test population of cells, and obtaining an immunogenic response of thepopulation of cells. BAHRAMI S, LUND LAURSEN A, MELCHJORSEN J, OSTERGAARD L J, RYTTERGAARD DUCH M, SCHMELTZ SOGAARD O, SKOU PEDERSEN F, TOFT NIELSEN L, TOLSTRUP M.248.

252. WO2010112033-A2; WO2010112033-A3. Estimating disease risk of individualhaving/developing multiple sclerosis involves in genetic material sample fromindividual, assessing sequence polymorphism in specific genetic regions ofhuman chromosome, obtaining and estimating step.
ANDERSEN NEXO B, CHRISTENSEN T, LASKA M J, MOLLER LARSEN A, SKOU PEDERSEN F, VILLESEN FREDSTED P